Quinton Cardiology to Promote Heart-Risk Test

An agreement to promote and distribute a heart-risk test called microvolt T-wave alternans (MTWA) has been announced by Quinton Cardiology (Bothell, WA, USA). The test was developed by Cambridge Heart, Inc. (Bedford, MA, USA).

The T-wave alternans test will be fully integrated in the Burdick brand stress systems of Quinon Cardiology. Both companies agreed to continue joint efforts to build market awareness and expand the market for the MTWA test, a noninvasive risk stratifier of sudden cardiac death. The test measures extremely subtle beat-to-beat fluctuations in a patient's heartbeat called T-wave alternans. These variations, measured at one millionth of a volt, are detected in any clinical setting where titration of the heart rate is possible.

During the test, proprietary sensors are placed on a patient's chest. Clinical research has shown that patients with symptoms of, or at risk for, life-threatening arrhythmias who test positive for T-wave alternans are at significant risk for subsequent sudden cardiac events, including sudden death, while those who test negative are at minimal risk.

"The Burdick brand and distribution channel will continue to help us bring the message of MTWA to many physicians whom we would not be able to reach on our own,” said David Chazanovitz, president and CEO of Cambridge Heart.





Related Links:
Quinton
Cambridge